Clinical Trial

Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-09-16; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2022-02-16
Trial Details
NCT Number NCT04559230
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions Recurrent Glioblastoma
Enrollment 32 participants
Start Date 2022-01-06
Primary Completion 2027-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-30